COMMUNIQUÉS West-GlobeNewswire

Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting
17/03/2026
WALTHAM, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer [...]
Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.
17/03/2026
Dallas, Texas, March 17, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals,” the “Company,” or “MangoRx”), a company focused on developing, marketing, and selling health and wellness products [...]
Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
17/03/2026
Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations and four cancer types, including first evidence of activity in gastric cancer, reinforcing broad [...]
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
17/03/2026
MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and [...]
Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting
17/03/2026
Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting (OXFORDSHIRE, England & GAITHERSBURG, Md., & RADNOR, Penn., US, 17 March 2026) Immunocore [...]
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17/03/2026
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that on March 16, 2026 the Company’s Compensation Committee of the Board of Directors (the “ [...]
Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
17/03/2026
REDWOOD CITY, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]
Evaxion to present new data at AACR Annual Meeting
17/03/2026
Two abstracts accepted for presentation One abstract on new additional biomarker and immunogenicity data for personalized cancer vaccine EVX-01 Another abstract on the use of Evaxion’s AI-Immunology™ platform in [...]
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival
17/03/2026
NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced it will [...]
Akari Therapeutics Announces ADS Ratio Change
17/03/2026
TAMPA, Fla. and LONDON, March 17, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, [...]
Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial
17/03/2026
Data was published in the Online Itinerary Planner for the 2026 AACR Annual Meeting, and is scheduled to be presented at the meeting on April 19th GARDEN CITY, N.Y., March 17, 2026 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd [...]
Longeveron Announces 2025 Full Year Financial Results and Provides Business Update
17/03/2026
On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan- [...]
Enara Bio to Unveil First‑in‑Class DARKFOX‑Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential for Solid Tumor Immunotherapy
17/03/2026
Oxford, UK – March 17, 2026. Enara Bio , a pioneer in Dark Antigen® discovery and bispecific T cell engager innovation, today announced new data to be presented at the American Association for Cancer Research (AACR) [...]
Kestra Medical Technologies Reports Third Quarter Fiscal 2026 Financial Results
17/03/2026
KIRKLAND, Wash., March 17, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported financial results for the third [...]
SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference
17/03/2026
- Preclinical data show that SLS009 lowers the apoptotic threshold in AML cells by suppressing critical survival pathways - NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“ [...]
Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting
17/03/2026
New clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21 Preclinical data highlight combination potential for ZW191, a folate receptor alpha (FR ⍺ )-targeting antibody-drug [...]
Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026
17/03/2026
Preclinical evidence supports azenosertib ADC combinations as potential promising therapeutic strategies for Triple-Negative Breast Cancer Demonstration of Cyclin E1 protein overexpression as an indicator for poor [...]
Virbac : résultats annuels 2025
17/03/2026
Une marge opérationnelle 2 robuste de 16,3 %, portée par une solide croissance organique du chiffre d'affaires de 7,9 %. Dynamique 2025 solide avec un chiffre d'affaires annuel en hausse de +7,9 % à périmètre et taux de [...]
Naturonel Launches Made-in-USA Herbal Supplements to Support Metabolic Wellness
17/03/2026
New line of plant-based dietary supplements tested for purity and potency now available to consumers nationwide. Naturonel Image PRINCETON, N.J., March 17, 2026 (GLOBE NEWSWIRE) -- Naturonel, a wellness brand focused on [...]

Pages